| |
著者: Trang T H Tu, Miho Takenoshita, Hirofumi Matsuoka, Takeshi Watanabe, Takayuki Suga, Yuma Aota, Yoshihiro Abiko, Akira Toyofuku
雑誌名: Biopsychosoc Med. 2019;13:1. doi: 10.1186/s13030-019-0142-7. Epub 2019 Jan 31.
Abstract/Text
Burning Mouth Syndrome (BMS), a chronic intraoral burning sensation or dysesthesia without clinically evident causes, is one of the most common medically unexplained oral symptoms/syndromes. Even though the clinical features of BMS have been astonishingly common and consistent throughout the world for hundreds of years, BMS remains an enigma and has evolved to more intractable condition. In fact, there is a large and growing number of elderly BMS patients for whom the disease is accompanied by systemic diseases, in addition to aging physical change, which makes the diagnosis and treatment of BMS more difficult. Because the biggest barrier preventing us from finding the core pathophysiology and best therapy for BMS seems to be its heterogeneity, this syndrome remains challenging for clinicians. In this review, we discuss currently hopeful management strategies, including central neuromodulators (Tricyclic Antidepressants - TCAs, Serotonin, and Norepinephrine Reuptake Inhibitors - SNRIs, Selective Serotonin Reuptake Inhibitors - SSRIs, Clonazepam) and solutions for applying non-pharmacology approaches. Moreover, we also emphasize the important role of patient education and anxiety management to improve the patients' quality of life. A combination of optimized medication with a short-term supportive psychotherapeutic approach might be a useful solution.
PMID 30733824 Biopsychosoc Med. 2019;13:1. doi: 10.1186/s13030-019-0142-7. Epub 2019 Jan 31.
|
